Compare Illumina, Inc. (ILMN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Illumina, Inc. trades at $192.8 (market cap $27.94B), while Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M). The key difference: Illumina, Inc. is far larger — about 313× Inovio Pharmaceuticals Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | INO | |
|---|---|---|
Market Cap | $27.94B | $89.27M |
Sector | Health | Health |
52-Week High | $194.33 | $2.87 |
52-Week Low | $91.00 | $1.05 |
Enterprise Value | $29.33B | $60.28M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
